S
CLPT icon

SignatureFD’s ClearPoint Neuro CLPT Stock Holding History

SignatureFD’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10
Closed -$85 – 3296
2022
Q4 		$85 Hold
10
– – ﹤0.01% 3233
2022
Q3 		$0 Hold
10
– – ﹤0.01% 3130
2022
Q2 		$0 Hold
10
– – ﹤0.01% 3140
2022
Q1 		$0 Buy
+10
New +$91 ﹤0.01% 3167

Other funds holding CLPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
CWM
Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

SignatureFD's CLPT Position: Q1 2023 in Review

SignatureFD sold out of ClearPoint Neuro (CLPT) in Q1 2023, closing a stake of 10 shares — an estimated $85 sold.

SignatureFD first reported a position in CLPT in Q1 2022 and held it in 4 quarters. The position peaked at $85 in Q4 2022. 59 funds tracked by Wall St. Rank hold CLPT as of Q1 2023.

  • SignatureFD reported no remaining ClearPoint Neuro position as of Q1 2023 after selling out during the quarter.
  • SignatureFD sold 10 ClearPoint Neuro shares in Q1 2023, an estimated $85.
  • SignatureFD first reported a position in ClearPoint Neuro in Q1 2022 and held it in 4 quarters.
  • SignatureFD's ClearPoint Neuro position peaked at $85 in Q4 2022.
  • 59 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2023.

Based on SignatureFD's 13F filing for Q1 2023, filed 28 Apr 2023.